fenoldopam

Summary

Summary: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

Top Publications

  1. Tumlin J, Wang A, Murray P, Mathur V. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894-903 pubmed
    ..b>Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow (RPF) in patients with normotensive ..
  2. Morcos S. Prevention of contrast media nephrotoxicity--the story so far. Clin Radiol. 2004;59:381-9 pubmed
    ..manipulation with renal vasodilators (calcium channel blockers, dopamine, atrial natriuretic peptide, fenoldopam (selective dopamine-1 receptor agonist), prostaglandin E(1), non-selective adenosine receptors antagonist (..
  3. Aravindan N, Natarajan M, Shaw A. Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure. J Cardiothorac Vasc Anesth. 2006;20:179-86 pubmed
    ..gene transcription, including nuclear factor kappa B (NF-kappaB), in renal tissues, but the molecular effects of fenoldopam in this setting are not known...
  4. Allaqaband S, Tumuluri R, Malik A, Gupta A, Volkert P, Shalev Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279-83 pubmed
    The objective of this study was to compare the efficacy of N-acetylcysteine (NAC), fenoldopam, and saline in preventing radiocontrast-induced nephropathy (RCIN) in high-risk patients undergoing cardiovascular procedures...
  5. Stephens C, Jandhyala B. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002;24:301-13 pubmed
    ..to: a) comparatively evaluate the effects of clevidipine, a new dihydropyridine calcium antagonist, and fenoldopam, a dopamine (D-1) receptor agonist on basal renal function, and b) to determine the efficacy of these agents in ..
  6. Morelli A, Ricci Z, Bellomo R, Ronco C, Rocco M, Conti G, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med. 2005;33:2451-6 pubmed
    Acute renal failure is common in septic patients. Fenoldopam, a dopamine-1 receptor agonist, increases renal blood flow and may, therefore, reduce the risk of acute renal failure in such patients...
  7. Tumlin J, Dunbar L, Oparil S, Buckalew V, Ram C, Mathur V, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med. 2000;7:653-62 pubmed
    ..To examine the safety and efficacy of fenoldopam, the first antihypertensive with selective and specific action on vascular dopamine (DA1) receptors, in a ..
  8. Lechner B, Pascual J, Roscelli J. Failure of fenoldopam to control severe hypertension secondary to renal graft rejection in a pediatric patient. Mil Med. 2005;170:130-2 pubmed
    We report the first case of the failure of fenoldopam for a pediatric patient with severe hypertension and renal failure...
  9. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 2001;53:341-5 pubmed
    We evaluated the ability of fenoldopam, a newly available renal vasodilator, to prevent radiocontrast nephropathy in high-risk patients undergoing interventional diagnostic and therapeutic angiographic procedures...

More Information

Publications69

  1. Halpenny M, Lakshmi S, O DONNELL A, O Callaghan Enright S, Shorten G. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia. 2001;56:953-60 pubmed
    ..We hypothesised that fenoldopam, a selective dopamine receptor agonist, would preserve renal function after cardiopulmonary bypass through its ..
  2. Stone G, McCullough P, Tumlin J, Lepor N, Madyoon H, Murray P, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-91 pubmed
    ..b>Fenoldopam mesylate, a specific agonist of the dopamine-1 receptor, preserves renal blood flow after iodinated contrast ..
  3. Umrani D, Goyal R. Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats. Clin Exp Hypertens. 2003;25:221-33 pubmed
    ..We have studied the effect of six-week treatment with D1 receptor agonist fenoldopam (1 mg/kg, i.p...
  4. Kini A, Sharma S. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med. 2001;2 Suppl 1:S19-25 pubmed
    ..Our nonrandomized data suggest that in adequately hydrated patients, the dopamine-1 receptor agonist fenoldopam is a useful adjunct during PCI for prevention of RCN, reducing its incidence to less than 5%...
  5. Brogden R, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs. 1997;54:634-50 pubmed
    b>Fenoldopam is a dopamine agonist that causes peripheral vasodilation via stimulation of dopamine 1 (D1) receptors...
  6. Varon J, Marik P. The diagnosis and management of hypertensive crises. Chest. 2000;118:214-27 pubmed
    ..This article reviews some of the current concepts and common misconceptions in the management of patients with acutely elevated BP...
  7. Landoni G, Biondi Zoccai G, Marino G, Bove T, Fochi O, Maj G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2008;22:27-33 pubmed publisher
    ..To determine the efficacy of fenoldopam in the prevention of acute renal failure, the authors performed a systematic review of randomized, controlled ..
  8. Caimmi P, Pagani L, Micalizzi E, Fiume C, Guani S, Bernardi M, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:491-4 pubmed
    To evaluate the possible protective effects of fenoldopam on renal function in patients undergoing cardiopulmonary bypass. Prospective, randomized trial. University teaching hospital...
  9. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 2004;44:12-24 pubmed
    ..Recent advances have examined the impact of fenoldopam (dopamine-1 [DA-1] receptor; DA-1 agonist), the antioxidant N-acetylcysteine, iso-osmolar contrast agents, ..
  10. Ng M, Tremmel J, Fitzgerald P, Fearon W. Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy. J Interv Cardiol. 2006;19:75-9 pubmed
    ..To date, vasodilator therapies such as fenoldopam have failed to prevent CIN, possibly because significant hypotension as a result of systemic infusion has ..
  11. Teirstein P, Price M, Mathur V, Madyoon H, Sawhney N, Baim D. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol. 2006;97:1076-81 pubmed
    A randomized, controlled clinical trial demonstrated that intravenous (IV) fenoldopam did not prevent further deterioration in renal function after contrast administration in patients with chronic renal insufficiency...
  12. Yi X, Zhang G, Yuan J. Renoprotective role of fenoldopam pretreatment through hypoxia-inducible factor-1alpha and heme oxygenase-1 expressions in rat kidney transplantation. Transplant Proc. 2013;45:517-22 pubmed publisher
    Donor preconditioning by fenoldopam is demonstrated to improve graft function in recipients...
  13. Shusterman N, Elliott W, White W. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161-8 pubmed
    ..b>Fenoldopam, a novel, peripherally acting dopamine-1 agonist, lowers blood pressure through arteriolar vasodilation, with ..
  14. Umrani D, Goyal R. Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats. Clin Exp Hypertens. 2002;24:207-19 pubmed
    We have studied the effect of chronic treatment with dopamine D1 receptor agonist fenoldopam (1 mg/kg, i.p. daily for 6 weeks) on renal function and metabolic parameters in streptozotocin (STZ)-diabetic rats...
  15. Tumlin J. Impaired blood flow in acute kidney injury: pathophysiology and potential efficacy of intrarenal vasodilator therapy. Curr Opin Crit Care. 2009;15:514-9 pubmed publisher
    ..Recent studies confirm that higher doses of fenoldopam or other vasodilators can be administered intrarenally without the development of systemic hypotension...
  16. Knoderer C, Leiser J, Nailescu C, Turrentine M, Andreoli S. Fenoldopam for acute kidney injury in children. Pediatr Nephrol. 2008;23:495-8 pubmed
    ..requiring treatment with ventricular assist devices who developed acute kidney injury and were treated with fenoldopam. Therapy with fenoldopam appeared successful in one case in that renal replacement therapy was avoided with ..
  17. Sorbello M, Morello G, Paratore A, Cutuli M, Mistretta G, Belluoccio A, et al. Fenoldopam vs dopamine as a nephroprotective strategy during living donor kidney transplantation: preliminary data. Transplant Proc. 2007;39:1794-6 pubmed
    b>Fenoldopam is a selective DA1 agonist with potential nephroprotective capabilities...
  18. Meco M, Cirri S. The effect of various fenoldopam doses on renal perfusion in patients undergoing cardiac surgery. Ann Thorac Surg. 2010;89:497-503 pubmed publisher
    The hypothesis that fenoldopam mesylate, by increasing renal flow, could reduce renal damage in patients undergoing cardiac surgery with cardiopulmonary bypass has gained great interest...
  19. Barr L, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med. 2008;36:1427-35 pubmed publisher
    To determine whether fenoldopam and N-acetylcysteine prevent renal deterioration and improve hospital outcome for patients with chronic renal insufficiency undergoing cardiac surgery...
  20. Kini A, Mitre C, Kim M, Kamran M, Reich D, Sharma S. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv. 2002;55:169-73 pubmed
    ..The purpose of this study was to evaluate whether the selective dopamine-1 (DA-1) receptor agonist fenoldopam would be beneficial in patients with chronic renal insufficiency (CRI) undergoing PCI and also to design a ..
  21. Zangrillo A, Biondi Zoccai G, Frati E, Covello R, Cabrini L, Guarracino F, et al. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. J Cardiothorac Vasc Anesth. 2012;26:407-13 pubmed publisher
    ..of acute kidney injury seems to be available, the authors updated a meta-analysis to investigate the effects of fenoldopam in reducing acute kidney injury in patients undergoing cardiac surgery, focusing on randomized placebo-..
  22. Aravindan N, Samuels J, Riedel B, Shaw A. Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. Kidney Blood Press Res. 2006;29:165-74 pubmed
    Vasoactive compounds are known to affect intrarenal hemodynamics and gene transcription, but specific effects of fenoldopam in the setting of acute renal ischemia are not known...
  23. Costello J, Thiagarajan R, Dionne R, Allan C, Booth K, Burmester M, et al. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr Crit Care Med. 2006;7:28-33 pubmed
    b>Fenoldopam, a selective dopamine-1 receptor agonist, causes systemic vasodilation and increased renal blood flow and tubular sodium excretion...
  24. Ranucci M, De Benedetti D, Bianchini C, Castelvecchio S, Ballotta A, Frigiola A, et al. Effects of fenoldopam infusion in complex cardiac surgical operations: a prospective, randomized, double-blind, placebo-controlled study. Minerva Anestesiol. 2010;76:249-59 pubmed
    b>Fenoldopam mesylate is a short-acting dopamine-1 agonist that has been suggested to be a possible reno-protective agent in patients undergoing cardiac surgery...
  25. Kellum J. Prophylactic fenoldopam for renal protection? No, thank you, not for me--not yet at least. Crit Care Med. 2005;33:2681-3 pubmed
  26. Garwood S, Swamidoss C, Davis E, Samson L, Hines R. A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth. 2003;17:17-21 pubmed
    To evaluate the usefulness of low-dose fenoldopam mesylate in patients at risk of developing renal dysfunction after cardiac surgery requiring cardiopulmonary bypass. A prospective, single-center, observational study...
  27. Ng T, Shurmur S, Silver M, Nissen L, O Leary E, Rigmaiden R, et al. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int J Cardiol. 2006;109:322-8 pubmed
    N-acetylcysteine and fenoldopam are commonly prescribed for prevention of contrast mediated nephropathy, however, comparative superiority of either agent is unknown...
  28. Salahudeen A, Yang M, Huang H, DORE S, Stec D. Fenoldopam preconditioning: role of heme oxygenase-1 in protecting human tubular cells and rodent kidneys against cold-hypoxic injury. Transplantation. 2011;91:176-82 pubmed publisher
    ..To test whether preconditioning with fenoldopam (FD) induce HO-1 and protect kidneys against cold storage injury and whether HO-1 plays a role in protection...
  29. Adluri R, Singh A, Skoyles J, Robins A, Hitch A, Baker M, et al. The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass. Eur J Cardiothorac Surg. 2009;35:988-94 pubmed publisher
    ..b>Fenoldopam, a dopamine analog (DA-1 receptor agonist), has recently been shown to be specific reno-splanchnic vasodilator ..
  30. Tumlin J, Finkel K, Murray P, Samuels J, Cotsonis G, Shaw A. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis. 2005;46:26-34 pubmed
    ..b>Fenoldopam is a dopamine receptor alpha1-specific agonist that increases renal blood flow in patients with kidney failure...
  31. Bove T, Landoni G, Calabrò M, Aletti G, Marino G, Cerchierini E, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation. 2005;111:3230-5 pubmed
    ..The aim of this study was to evaluate the usefulness of fenoldopam, a specific agonist of the dopamine-1 receptor, in patients at high risk of perioperative renal dysfunction...
  32. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2004;44:762-5 pubmed
    We performed a study to assess the efficacy of fenoldopam mesylate (a specific agonist of the dopamine-1 receptor) as compared with N-acetylcysteine (NAC) in preventing contrast agent-associated nephrotoxicity (CAN)...
  33. Gilbert T, Hasnain J, Flinn W, Lilly M, Benjamin M. Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther. 2001;6:31-6 pubmed
    ..b>Fenoldopam mesylate is a novel, highly selective dopamine type-1 agonist that preferentially dilates the renal and ..
  34. Moffett B, Mott A, Nelson D, Goldstein S, Jefferies J. Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review. Pediatr Crit Care Med. 2008;9:403-6 pubmed publisher
    Published data describe the use of fenoldopam in adults for treatment of oliguria/anuria and for renal perfusion and protection, but pediatric data are scant...
  35. Kini A, Mitre C, Kamran M, Suleman J, Kim M, Duffy M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol. 2002;89:999-1002 pubmed
  36. Della Rocca G, Pompei L, Costa M, Coccia C, Scudeller L, Di Marco P, et al. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesth Analg. 2004;99:1604-9, table of contents pubmed
    ..effects on serum creatinine (CRE), blood urea nitrogen (BUN), and urine output of small-dose dopamine and fenoldopam in patients undergoing liver transplantation, we randomized 43 patients to 1 of 2 continuous infusions over 48 h,..
  37. Cogliati A, Vellutini R, Nardini A, Urovi S, Hamdan M, Landoni G, et al. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth. 2007;21:847-50 pubmed
    The purpose of this study was to evaluate the renoprotective effects of fenoldopam in patients at high risk of postoperative acute kidney injury undergoing elective cardiac surgery requiring cardiopulmonary bypass...
  38. Landoni G, Biondi Zoccai G, Tumlin J, Bove T, De Luca M, Calabrò M, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis. 2007;49:56-68 pubmed
    Acute kidney injury is common in critically ill patients. Fenoldopam mesylate is a potent dopamine A-1 receptor agonist that increases blood flow to the renal cortex and outer medulla...
  39. Brienza N, Malcangi V, Dalfino L, Trerotoli P, Guagliardi C, Bortone D, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med. 2006;34:707-14 pubmed
    b>Fenoldopam mesylate is a selective dopamine-1 agonist, with no effect on dopamine-2 and alpha1 receptors, producing a selective renal vasodilation. This may favor the kidney oxygen supply/demand ratio and prevent acute renal failure...
  40. Ricci Z, Luciano R, Favia I, Garisto C, Muraca M, Morelli S, et al. High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Crit Care. 2011;15:R160 pubmed publisher
    The aim of the study was to evaluate the effects of high-dose fenoldopam, a selective dopamine-1 receptor, on renal function and organ perfusion during cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD)...
  41. Ranucci M, Soro G, Barzaghi N, Locatelli A, Giordano G, Vavassori A, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg. 2004;78:1332-7; discussion 1337-8 pubmed
    ..The aim of this study was to determine if prophylactic treatment with fenoldopam mesylate of patients at high risk of postoperative acute renal failure reduced the incidence of this event...
  42. Ricci Z, Stazi G, Di Chiara L, Morelli S, Vitale V, Giorni C, et al. Fenoldopam in newborn patients undergoing cardiopulmonary bypass: controlled clinical trial. Interact Cardiovasc Thorac Surg. 2008;7:1049-53 pubmed publisher
    We determined if low dose fenoldopam in neonates already receiving conventional diuretics improves urine output, fluid balance, acute kidney injury incidence (AKI) and time to extubation...
  43. Sehgal C, Arger P, Silver A, Patton J, Saunders H, Bhattacharyya A, et al. Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study. Radiology. 2001;219:419-26 pubmed
    ..Doppler ultrasonography (US) for assessing renal blood flow changes induced with endothelin-1 (ET-1) and fenoldopam mesylate in conscious dogs...
  44. Walker P, Brokering K, Theobald J. Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy. 2003;23:1617-26 pubmed
    ..45% sodium chloride before and after administration of contrast material. Recently, N-acetylcysteine and fenoldopam have been studied to determine their efficacy in preventing RCIN...
  45. Prielipp R, Wall M, Groban L, Tobin J, Fahey F, Harkness B, et al. Reduced regional and global cerebral blood flow during fenoldopam-induced hypotension in volunteers. Anesth Analg. 2001;93:45-52 pubmed
    ..A new, selective dopamine-1 agonist, fenoldopam, is a potent systemic vasodilator with moderate alpha(2)-receptor affinity...
  46. Yakazu Y, Iwasawa K, Narita H, Kindscher J, Benson K, Goto H. Hemodynamic and sympathetic effects of fenoldopam and sodium nitroprusside. Acta Anaesthesiol Scand. 2001;45:1176-80 pubmed
    b>Fenoldopam is a novel dopamine-1 receptor selective agonist that can be used as a vasodilator perioperatively to treat hypertension and to produce induced hypotension...
  47. Khanna A, McCullough P. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. Rev Cardiovasc Med. 2003;4:255-9 pubmed
    ..Without treatment, the survival rate for malignant hypertension is 10% to 35%. With appropriate treatment, the 5-year survival rate is 75%. ..
  48. Laake J, Bugge J. Prevention of acute renal failure--first do no harm!. Acta Anaesthesiol Scand. 2006;50:255-6; author reply 256-8 pubmed
  49. Dobbins D. Receptor mechanisms of prenodal lymphatic constriction by dopamine. Regul Pept. 2003;114:7-13 pubmed
    ..These lymph vessels do contain both DA(1)- and DA(2)-receptors but stimulation of these receptors results in lymphatic smooth muscle relaxation. ..
  50. Zhang Y, Yuan Z. Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. Clin Exp Pharmacol Physiol. 2010;37:613-8 pubmed publisher
    ..adenosine monophosphate accumulation and Na(+)/K(+)-ATPase inhibition induced by the D(1) receptor agonist fenoldopam. 4...
  51. Casagrande C, Merlo L, La Regina A. Development of dopaminergic drugs for the chronic treatment of congestive heart failure. J Auton Pharmacol. 1990;10 Suppl 1:s85-93 pubmed
    ..2. On the one hand, a selective DA-1 receptor agonist, such as fenoldopam, has been investigated as an agent developed for the stimulation of vascular and tubular DA-1 receptors in the ..
  52. Yu P, Eisner G, Yamaguchi I, Mouradian M, Felder R, Jose P. Dopamine D1A receptor regulation of phospholipase C isoform. J Biol Chem. 1996;271:19503-8 pubmed
    In LTK- cells stably transfected with rat D1A receptor cDNA, fenoldopam, a D1 agonist, increased phosphatidylinositol 4, 5-bisphosphate hydrolysis in a time-dependent manner...
  53. Watanabe H, Xu J, Bengra C, Jose P, Felder R. Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4. Kidney Int. 2002;62:790-8 pubmed
    ..Protein expression was assessed by immunoblotting. In human renal proximal tubule cells, the D1 agonist, fenoldopam, increased cAMP accumulation (73 +/- 2%)...
  54. Mathur V. The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev Cardiovasc Med. 2003;4 Suppl 1:S35-40 pubmed
    b>Fenoldopam, a selective agonist of dopamine-1 receptors, is a regional and systemic vasodilator...
  55. Venkatesh G. Development of controlled-release SK&F 82526-J buffer bead formulations with tartaric acid as the buffer. Pharm Dev Technol. 1998;3:477-85 pubmed
    ..controlled-release bead formulation for oral administration with buffer crystals as a carrier for loading of fenoldopam mesylate, an intravenous antihypertensive agent, which provides an in vitro release rate of 30-50 mg/hr for 6-8 ..
  56. De Shong D, Mathis A. Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy. Pharmacotherapy. 2004;24:819-20; author reply 820 pubmed
  57. Holcslaw T, Beck T. Clinical experience with intravenous fenoldopam. Am J Hypertens. 1990;3:120S-125S pubmed
    b>Fenoldopam (Corlopam), a new dopaminergic agent in clinical development by SmithKline Beecham Pharmaceuticals, is a dopamine-1 (DA1) agonist at post-synaptic dopamine receptors...
  58. Lema G, Aeschlimann N. To dilate or not to dilate. Anesth Analg. 2005;101:1241-2, author reply 1242 pubmed
  59. Dalmas D, Scicchitano M, Chen Y, Kane J, Mirabile R, Schwartz L, et al. Transcriptional profiling of laser capture microdissected rat arterial elements: fenoldopam-induced vascular toxicity as a model system. Toxicol Pathol. 2008;36:496-519 pubmed publisher
    ..elements of mesenteric arteries (MA) from untreated rats and rats given a single vasotoxic dose of 100 mg/kg Fenoldopam and euthanized 1 or 4 hours postdose was assessed...
  60. Asif A, Epstein D, Epstein M. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy. J Clin Pharmacol. 2004;44:1342-51 pubmed
    ..Recently, studies have been initiated to evaluate the potential of a selective dopamine-1 receptor agonist (fenoldopam) in ameliorating radiocontrast-induced renal failure...